Clinical Questions #6

Does celecoxib increase cardiovascular risk?
Brian J Mayer, MD; Randall Lamfers, MD; David A Feldstein MD

Patient
A 50-year-old woman with no coronary risk factors and a history of peptic ulcer disease is taking rofecoxib for osteoarthritis. She has tried acetaminophen and did not receive as much relief for her pain as she does with the rofecoxib. Since rofecoxib was voluntarily withdrawn from the market for increased cardiovascular events, she wants to know if her cardiovascular risk would be increased if she switched to celecoxib.

Clinical Question
In low-risk patients does celecoxib increase the risk of cardiovascular events?

How and where could you locate evidence to answer this question?

________________________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________

How would you treat this patient?

________________________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________
________________________________________________________________________________________

Turn the page for one possible approach.

Authors are with the University of Wisconsin Hospital and Clinics. Doctor Mayer and Doctor Lamfers are both chief residents in Internal Medicine. Doctor Feldstein is an academic hospitalist. He is also an assistant professor in the Department of Medicine at the University of Wisconsin-Madison.
Search Strategy
1. EBM search of ACP Journal Club, DARE, and Cochrane Database of Systematic Reviews using the OVID interface May 2005 week 2:
   A. “cox2 or cyclooxygenase or celebrex or celecoxib or vioxx or rofecoxib”
   B. “MI or Myocardial Infarction or thrombosis or CVA or stroke or CAD or Cardiovascular”
   C. Combine [A] and [B]
   D. 30 Reviews—none of which specifically addressed our clinical question
2. Recent Medline (1996 to present May 2005 week 2) using OVID interface
   A. “Celebrex or celecoxib or vioxx or rofecoxib or cox2”
   B. “Exp Cardiovascular Diseases” (exploded MeSH heading)
   C. Combine [A] and [B] limit to human and English
   D. Limit [C] to “therapy (specificity)” under Clinical Queries
   E. 23 studies—one of which pertained to our clinical question

Study Characteristics
• 2035 patients at 91 different sites
• Age 32-88
• Patients with a history of colonic polyps
• Patients randomized into 3 groups
  o Placebo
  o Celecoxib 200 mg twice daily
  o Celecoxib 400 mg twice daily
• Main outcome was a composite endpoint of death from CV causes, myocardial infarction, stroke, or heart failure

Validity of Evidence
• Properly randomized trial
• Baseline risk factors for cardiovascular disease prospectively recorded
• Appropriately blinded
• 3-year follow up seemed short for cardiovascular events
• All patients completed 2.8-3.1 years of follow up
• Intention to treat analysis
• Study not specifically designed to detect cardiovascular events
• Retrospective attempt to evaluate safety
• Overall this study is of moderate methodological quality due to the retrospective evaluation of cardiac endpoints.

Results
• Trial was stopped early by the cardiovascular safety committee
• Composite endpoint of cardiovascular death, nonfatal MI, stroke, or heart failure were increased in both Celecoxib groups
• Hazard ratios (HR)
  o 200mg bid
    • HR 2.3, 95% CI 0.9 to 5.5
  o 400mg bid
    • HR 3.4, 95% CI 1.4 to 7.8
• Number Needed to Harm (NNH)
  o 200mg twice daily not significant
  o 400mg twice daily
    • NNH 43, 95% CI 16 to 252
• No individual endpoint reached statistical significance

Applying the Evidence to the Patient
• Patient is similar to those in the study.
• Celecoxib is a feasible intervention.
• Our patient’s cardiovascular risk is 1% over 10 years.
  o Calculated using the National Cholesterol Education Program’s cardiovascular risk calculator.
• Worst case scenario is that, using the high end of the confidence interval, our patient’s risk would increase to 5.5% over 10 years.

Summary
This is a good quality study that demonstrates increased risk for a composite endpoint of cardiovascular events. These results are consistent with the APPROVe trial that led to Vioxx being voluntarily taken off the market. Our patient had a very low baseline cardiovascular risk. Even with the increased risk of taking Celecoxib, her overall risk of cardiovascular events in the next 10 years remains relatively low. After a discussion about the potential risks, our patient ultimately chose not to use this medication since her insurance provider would not cover it.

Conclusion
Celecoxib increases the risk of cardiovascular events. The patient’s baseline risk should be taken into account when prescribing this medication. Before prescribing Celecoxib, an informed discussion should be held with the patient about the risks, benefits and alternatives, especially as this medication has not been shown to be more effective than other NSAIDs.

References:
The mission of the *Wisconsin Medical Journal* is to provide a vehicle for professional communication and continuing education of Wisconsin physicians.

The *Wisconsin Medical Journal* (ISSN 1098-1861) is the official publication of the Wisconsin Medical Society and is devoted to the interests of the medical profession and health care in Wisconsin. The managing editor is responsible for overseeing the production, business operation and contents of the *Wisconsin Medical Journal*. The editorial board, chaired by the medical editor, solicits and peer reviews all scientific articles; it does not screen public health, socioeconomic or organizational articles. Although letters to the editor are reviewed by the medical editor, all signed expressions of opinion belong to the author(s) for which neither the *Wisconsin Medical Journal* nor the Society take responsibility. The *Wisconsin Medical Journal* is indexed in Index Medicus, Hospital Literature Index and Cambridge Scientific Abstracts.

For reprints of this article, contact the *Wisconsin Medical Journal* at 866.442.3800 or e-mail wmj@wismed.org.

© 2005 Wisconsin Medical Society